ReviewFrontiers in endocrinology2025
Hypertonic dextrose prolotherapy in osteoarthritis: mechanisms, efficacy, and future research directions.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07381621 (A Prospective Evaluation of the Clinical Effectiveness of Perineural Dextrose and Conventional Local Anesthetic Injections in Patients With Symptomatic Knee Osteoarthritis), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Evaluation of the Clinical Effectiveness of Perineural Dextrose and Conventional Local Anesthetic Injections in Patients With Symptomatic Knee Osteoarthritis
Who cites it
4 citing papers in PubMed.
- Management of Musculoskeletal Injuries with an Inflammatory Damage-Associated Molecular Pattern (DAMP) Etiology.Pain and therapy · 2026Review
- Dextrose Injections Across Temporomandibular Joint Mobility Disorders: A Scoping Review.Journal of clinical medicine · 2026Review
- A narrative review of clinical research on knee osteoarthritis in 2025.Annals of joint · 2026Review
- Prolotherapy for temporomandibular joint disorders: an updated comprehensive review.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disease that causes pain, stiffness, and reduced mobility, significantly affecting the quality of life for millions globally. Current treatments focus on symptom management, with limited efficacy in addressing the underlying disease progression. Hypertonic dextrose prolotherapy (DPT) has emerged as a potential regenerative treatment, utilizing dextrose injections to stimulate the body's natural healing mechanisms by promoting tissue regeneration, strengthening ligaments, and improving joint function. Recent clinical studies, including the latest research findings, have shown that prolotherapy offers significant pain relief and functional improvement in knee OA, often outperforming other treatments like hyaluronic acid (HA) and corticosteroid injections. Despite promising results, the efficacy of prolotherapy varies across studies due to differences in protocols and study designs. Challenges remain, including lack of standardization, methodological bias, and short-term follow-up. Future research with rigorous designs and long-term follow-ups is necessary to establish prolotherapy's role in OA management, ensuring a more comprehensive understanding of its therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.